Profil
Georges Rawadi served as the Chief Executive Officer and Executive Director at Celyad Oncology SA in 2023 and as the Chief Executive Officer and Director at YSOPIA Biosciences SA from 2018 to 2021.
Prior to that, he was the Vice President of Business Development at Celyad Oncology SA from 2014 to 2018 and held the same position at Cellectis SA. Rawadi holds a doctorate from Université Pierre et Marie Curie and a graduate degree from ESSEC Business School.
Ehemalige bekannte Positionen von Georges Rawadi
Unternehmen | Position | Ende |
---|---|---|
CELYAD ONCOLOGY SA | Vorstandsvorsitzender | 01.12.2023 |
YSOPIA Biosciences SA
YSOPIA Biosciences SA BiotechnologyHealth Technology LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France. | Vorstandsvorsitzender | 01.09.2021 |
CELYAD ONCOLOGY SA | Corporate Officer/Principal | 23.03.2018 |
CELLECTIS S.A. | Corporate Officer/Principal | - |
Ausbildung von Georges Rawadi
ESSEC Business School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
CELLECTIS S.A. | Health Technology |
Private Unternehmen | 2 |
---|---|
Université Pierre et Marie Curie | Consumer Services |
YSOPIA Biosciences SA
YSOPIA Biosciences SA BiotechnologyHealth Technology LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France. | Health Technology |